Company: CERO
Filing Date: 2025-11-19
Form Type: 10-Q
Source: 0001213900-25-112619
Chunk: 91

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-11-19
Form: 10-Q
Item: Item 1
Chunk 91
---
fees of $464,000, offset by an increase in accounting fees of $149,000 and an increase in director fees of $7,000. Additionally, during
the three months ended September 30, 2025 as compared to the three months ended September 30, 2024, salaries and benefits increased by
$50,000, and other general and administrative expenses increased by $167,000 primarily attributable to an increase in transfer agent and
filing fees.

Other Income (Expense), Net

Other expenses was $(494,000)
for the three months ended September 30, 2025 as compared to other income of $174,000 for the three months ended September 30, 2024, reflecting
a negative change of $668,000. The negative change was primarily due to the recording of a $170,000 gain from change in value of the Company’s
earnout liability during the three months ended September 30, 2024 as compared to $0 during the three months ended September 30, 2025
and the recording of a $500,000 write off of deferred offering costs during the three months ended September 30, 2025 as compared to $0
during the three months ended September 30, 2024.

Net loss and net loss attributable to common
stockholders

For the three months ended September 30, 2025 and 2024, net loss amounted
to $4,856,000 and $4,228,000, respectively, which represents an increase in net loss of $628,000, or 14.9%. During the three months ended
September 30, 2025, in connection with our Series D Preferred Stock down round triggering event, we recorded deemed dividends of $6,650,000.
Accordingly, for the three months ended September 30, 2025 and 2024, net loss attributable to common stockholders amounted to $11,506,000,
or $(9.10) per common share, and $4,228,000, or $(170.22) per common share, respectively.

39

Results of Operations for the Nine Months
Ended September 30, 2025 and 2024

The results of operations
for the nine months ended September 30, 2024 are pro forma as the period presented in the following table and discussion includes
the Predecessor for the period from January 1, 2024 through February 13